Catalyst Pharmaceuticals products
Agamree®
-
Generic: vamorolone (oral suspension)
-
Indication: treatment of Duchenne muscular dystrophy (patients aged 2 years and older)
-
Usage: once-daily oral suspension as prescribed
Firdapse®
-
Generic: amifampridine phosphate (tablets)
-
Indication: Lambert–Eaton myasthenic syndrome (LEMS) in adults and children (≥ 6 years)
-
Usage: oral tablets; dosing individualized—recently approved expanded max daily dose of up to 100 mg
Fycompa®
-
Generic: perampanel (controlled substance CIII)
-
Indication: epilepsy (partial-onset seizures, with or without generalization)
-
Usage: once-daily oral dosing as per seizure control and tolerability
No comments:
Post a Comment